comparemela.com

Latest Breaking News On - Rhythm pharmaceuticals - Page 15 : comparemela.com

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

31.01.2024 - Company to participate in fireside chats at Guggenheim’s 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) - Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), . Seite 1

Needham & Company LLC Reaffirms Buy Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Needham & Company LLC reissued their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research note published on Friday morning, Benzinga reports. They currently have a $50.00 price objective on the stock. RYTM has been the subject of a number of other reports. Wells Fargo & Company boosted their target […]

Rhythm Pharmaceuticals (RYTM) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research report report published on Friday morning, Benzinga reports. They currently have a $50.00 target price on the stock. A number of other equities research analysts have also recently issued reports on RYTM. Wells Fargo & […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.